相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors
Sally C. M. Lau et al.
CLINICAL LUNG CANCER (2021)
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer A Phase 1/2 Open-label Nonrandomized Clinical Trial
Caicun Zhou et al.
JAMA ONCOLOGY (2021)
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Keunchil Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.
Sai-Hong Ignatius Ou et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer
Sean Khozin et al.
CANCER (2019)
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Seonggyu Byeon et al.
CANCER RESEARCH AND TREATMENT (2019)
Real-World Treatment Patterns and Survival in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
M. Dersarkissian et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.
Marcelo Vailati Negrao et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)